These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 2471710

  • 1. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects.
    Spinder T, Spijkstra JJ, van den Tweel JG, Burger CW, van Kessel H, Hompes PG, Gooren LJ.
    J Clin Endocrinol Metab; 1989 Jul; 69(1):151-7. PubMed ID: 2471710
    [Abstract] [Full Text] [Related]

  • 2. Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women.
    Spinder T, Spijkstra JJ, Gooren LJ, Hompes PG, van Kessel H.
    J Clin Endocrinol Metab; 1989 Jan; 68(1):200-7. PubMed ID: 2491861
    [Abstract] [Full Text] [Related]

  • 3. Sex steroids and pulsatile luteinizing hormone release in men. Studies in estrogen-treated agonadal subjects and eugonadal subjects treated with a novel nonsteroidal antiandrogen.
    Gooren L, Spinder T, Spijkstra JJ, van Kessel H, Smals A, Rao BR, Hoogslag M.
    J Clin Endocrinol Metab; 1987 Apr; 64(4):763-70. PubMed ID: 3102546
    [Abstract] [Full Text] [Related]

  • 4. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M, Campaniello E, Michelacci L, Pareschi A, Ferrari P, Bolelli G, Flamigni C.
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [Abstract] [Full Text] [Related]

  • 5. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD.
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [Abstract] [Full Text] [Related]

  • 6. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [Abstract] [Full Text] [Related]

  • 7. Pulsatile luteinizing hormone release and ovarian steroid levels in female-to-male transsexuals compared to heterosexual women.
    Spinder T, Spijkstra JJ, Gooren LJ, Burger CW.
    Psychoneuroendocrinology; 1989 Aug; 14(1-2):97-102. PubMed ID: 2499904
    [Abstract] [Full Text] [Related]

  • 8. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.
    Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):165-72. PubMed ID: 2961784
    [Abstract] [Full Text] [Related]

  • 9. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D, Steingold K, Cedars M, Lu JK, Meldrum DR, Judd HL, Chang RJ.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [Abstract] [Full Text] [Related]

  • 10. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM.
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [Abstract] [Full Text] [Related]

  • 11. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome.
    Apter D, Bützow T, Laughlin GA, Yen SS.
    J Clin Endocrinol Metab; 1994 Jul; 79(1):119-25. PubMed ID: 8027216
    [Abstract] [Full Text] [Related]

  • 12. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M.
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [Abstract] [Full Text] [Related]

  • 13. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
    Judd HL, Rigg LA, Anderson DC, Yen SS.
    J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
    [Abstract] [Full Text] [Related]

  • 14. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE, Macchi M, Montanini V, Mongioi A, Maugeri G, Vicari E, Coniglione F, Sipione C, D'Agata R.
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [Abstract] [Full Text] [Related]

  • 15. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [Abstract] [Full Text] [Related]

  • 16. The effect of 6 weeks of testosterone treatment on pulsatile luteinizing hormone secretion in eugonadal female-to-male transsexuals.
    Scheele F, Hompes PG, Gooren LJ, Spijkstra JJ, Spinder T.
    Fertil Steril; 1991 Mar; 55(3):608-11. PubMed ID: 2001760
    [Abstract] [Full Text] [Related]

  • 17. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.
    Stuenkel CA, Dudley RE, Yen SS.
    J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483
    [Abstract] [Full Text] [Related]

  • 18. Modulation of pulsatile gonadotropin secretion by testosterone in man.
    Matsumoto AM, Bremner WJ.
    J Clin Endocrinol Metab; 1984 Apr; 58(4):609-14. PubMed ID: 6421864
    [Abstract] [Full Text] [Related]

  • 19. 17 beta-Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals.
    Pache TD, Hop WC, de Jong FH, Leerentveld RA, van Geldorp H, Van de Kamp TM, Gooren LJ, Fauser BC.
    Clin Endocrinol (Oxf); 1992 Jun; 36(6):565-71. PubMed ID: 1424181
    [Abstract] [Full Text] [Related]

  • 20. Effects of chronic hyperandrogenism and/or administered central nervous system insulin on ovarian manifestation and gonadotropin and steroid secretion.
    Allon MA, Leach RE, Dunbar J, Diamond MP.
    Fertil Steril; 2005 Apr; 83 Suppl 1():1319-26. PubMed ID: 15831308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.